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 Prenatal diagnosis is traditionally made via invasive procedures such as 
amniocentesis and chorionic villus sampling (CVS).  However, both procedures carry a risk 
of complications, including miscarriage.  Many groups have spent years searching for a way 
to diagnose a chromosome aneuploidy without putting the fetus or the mother at risk for 
complications.  Non-invasive prenatal testing (NIPT) for chromosome aneuploidy became 
commercially available in the fall of 2011, with detection rates similar to those of invasive 
procedures for the common autosomal aneuploidies (Palomaki et al., 2011; Ashoor et al. 
2012; Bianchi et al. 2012).  Eventually NIPT may become the diagnostic standard of care 
and reduce invasive procedure-related losses (Palomaki et al., 2011).  The integration of 
NIPT into clinical practice has potential to revolutionize prenatal diagnosis; however, it also 
raises some crucial issues for practitioners.  Now that the test is clinically available, no 
studies have looked at the physicians that will be ordering the testing or referring patients to 
practitioners who do.  This study aimed to evaluate the attitudes of OB/GYN’s and how they 
are incorporating the test into clinical practice.  
 Our study shows that most physicians are offering this new, non-invasive technology 
to their patients, and that their practices were congruent with the literature and available 
professional society opinions.  Those physicians who do not offer NIPT to their patients 
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would like more literature on the topic as well as instructive guidelines from their 
professional societies.  Additionally, this study shows that the practices and attitudes of 
MFMs and OBs differ.  Our population feels that the incorporation of NIPT will change 
their practices by lowering the amount of invasive procedures, possibly replacing maternal 
serum screening, and that it will simplify prenatal diagnosis.  However, those physicians 
who do not offer NIPT to their patients are not quite sure how the test will affect their 
clinical practice. 
 From this study we are able to glean how physicians are incorporating this new 
technology into their practice and how they feel about the addition to their repertoire of 
tests.  This knowledge gives insight as to how to best move forward with the quickly 
changing field of prenatal diagnosis.  
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BACKGROUND 
 
Introduction 
There have been many advances in prenatal diagnosis in the last 50 years.  Initially, 
chromosome abnormalities like Down syndrome were diagnosed using an invasive 
procedure, amniocentesis.  An additional procedure, the chorionic villus sampling (CVS), 
was developed in order to diagnose abnormalities earlier in pregnancy.  Since then, both 
tests have become the standard of care in the prenatal diagnosis of chromosome 
abnormalities.  In an effort to identify affected pregnancies and decrease the amount of 
unnecessary invasive procedures, methods have been developed to evaluate a pregnancy 
utilizing the levels of certain analytes in maternal serum and ultrasound technology.  More 
recently a new technology, non-invasive prenatal testing (NIPT), allows for the 
identification of affected pregnancies through cell-free fetal DNA isolated from maternal 
serum.  This development has the potential to revolutionize the world of prenatal diagnosis.  
Our study aims to determine how obstetricians and gynecologists (OB/GYNs) are 
incorporating NIPT into their clinical practice as well as what their attitudes are regarding 
this new development. 
 
Prevalence 
Aneuploidy is a common type of chromosome abnormality, defined as having an 
extra or missing chromosome(s).  Down syndrome (Trisomy 21), Patau syndrome (Trisomy 
13), Edwards syndrome (Trisomy 18), and Turner syndrome (Monosomy 45) are the most 
common live born aneuploidies.  These chromosome abnormalities are compatible with life 
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but cause varying levels of morbidity and are identified in 0.65% of all newborns (Milunsky 
& Milunsky, 2009).  Many sex chromosome aneuploidies are also compatible with life, but 
not as common as those listed above.  Additionally, aneuploidies for the other autosomes 
have been identified in products of conception but are not compatible with life.  
Chromosome abnormalities have been identified in greater than 50% of clinically 
recognized early pregnancy losses (Gardner & Sutherland, 2004).  Out of all stillbirths and 
neonatal deaths, 6-11% of these fetuses have an aneuploidy (Alberman & Creasy, 1977).   
 
Invasive Diagnostic Testing 
The first diagnosis of trisomy 21, or Down syndrome, was made via amniocentesis in 
1968 (Valenti, Schutta, & Kehaty, 1968).  Further developments allowed the utilization of 
the amniocentesis procedure to enable health care providers to test levels of alpha 
fetoprotein (AFP) to screen for neural tube defects, conduct metabolic studies, and perform 
chromosome analysis on fetuses during the second trimester of pregnancy.  In the 1980’s, 
some physicians began using CVS as an alternative to amniocentesis (Lippman et al., 1992). 
The amniocentesis detects fetal aneuploidy >99% of the time, and CVS detects the same 
anomalies at a detection rate of >98% but does so in the first trimester.  However, both 
procedures are invasive and carry a risk of complications.  These complications can include 
spotting and cramping, infection, fluid leakage, and miscarriage.  According to the 
American Congress of Obstetricians and Gynecologists (ACOG), the rate of miscarriage 
following amniocentesis or CVS is 1/300-1/500 (“ACOG Practice Bulletin No. 77: 
Screening for fetal chromosomal abnormalities,” 2007; Eddleman et al., 2006). 
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Prenatal Screening 
Due to the risks associated with amniocentesis and CVS, various screening methods 
were developed to identify women who have an increased risk to have a pregnancy with 
certain chromosome aneuploidies.  Since there is a well-established association between 
advanced maternal age (AMA), i.e. being >35 years old, and Down syndrome, maternal age 
was the original “screening” tool (Hook, 1981).  It was then noted that pregnancies affected 
with Down syndrome had decreased levels of maternal serum AFP during the second 
trimester (Merkatz et al., 1984).  Additional markers have since been added and combined 
with maternal age to provide a risk assessment for certain conditions.  Over the last 30 years, 
prenatal screening has expanded to provide a risk assessment for the common chromosome 
aneuploidies: trisomy 21, 18, and 13 and can be performed in both the first and second 
trimesters.  The goal of prenatal screening is to identify the largest number of affected 
pregnancies (true positive screen) and minimize the amount of unaffected women told they 
are at risk (false positive screen); however, unaffected women are worried every day by 
positive screening tests (Ormond, 1997).   
First Trimester Screening 
In the first trimester screen, the fetal nuchal translucency (NT) is measured and 
combined with the biochemical markers, pregnancy-associated plasma protein A (PAPP-A) 
and beta human chorionic gonadotropin (b-hCG), in order to provide a likelihood that the 
fetus has Down syndrome or Trisomy 18 and is performed between 9 and 14 weeks 
gestation (Wapner et al., 2003).  Some labs will also provide a risk number for Trisomy 13.  
The detection rate for Down syndrome is 82-87% with a false positive rate of 5% (Malone et 
 4 
 
al., 2005).  The test detects 91-96% of cases of Trisomy 18/13, likely due to an increased 
nuchal translucency measurement (Malone et al., 2005; Spencer et al., 2000). 
Second Trimester Maternal Serum Screening 
Second trimester screening, most commonly called the “quadruple” screen, is 
performed between 15 and 22 weeks gestation and utilizes 4 analytes in maternal serum; 
AFP, hCG, unconjugated estriol (uE3), and dimeric inhibin A (DIA).  Characteristic patterns 
of the analytes combined with maternal age enable the laboratories to assign a risk to the 
pregnancy for fetal aneuploidy.  Levels of maternal serum AFP also assist in the detection of 
open neural tube defects like spina bifida.  The test has a detection rate of 80% for Down 
syndrome, and 60-75% for Trisomy 18 with a false positive rate of 5% (Malone et al., 
2005). 
Combined First and Second Trimester Maternal Serum Screening 
 Some screening methods involve combining both first and second trimester serum 
analytes and ultrasound markers in order achieve higher detection rates and lower false 
positive rates.  Depending on the method used, the detection rate for Down syndrome and 
Trisomy 18 is as high as 96% (Malone, 2005; Wald, 2004).  However, since this method 
requires that the patient return for multiple visits, it may not be the best option for everyone. 
Second Trimester Ultrasound 
In addition to maternal serum markers, ultrasound is also used as a tool to screen 
pregnancies for possible chromosome aneuploidy.  The full anatomy scan, or genetic 
sonogram in the second trimester can be used to support and/or adjust serum screening 
results, or on its own as a screening method (Bromley et al., 2002).  This ultrasound is 
ideally performed between 18 and 21 weeks gestation.  The scan can detect 59-87% of the 
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cases of Down syndrome, and 83-100% of the cases of Trisomy 13 and 18, (Breathnach, 
Fleming, & Malone, 2007). 
 
Non-invasive Prenatal Testing 
For some women who are flagged as having a higher risk for an abnormality based 
on advanced maternal age or maternal serum screening, an ultrasound may be enough to 
allay their fears, but for others the only way to lower their anxiety is the assurance only an 
invasive diagnostic procedure can give.  This choice, however, puts the pregnancy at risk for 
miscarriage.  For some women the risk of miscarriage is worth the knowledge and/or 
comfort the information gained can provide, but for others no amount of risk is ever worth 
the chance of losing a pregnancy.  For this reason, groups have spent years searching for an 
alternative; looking for a way to diagnose a chromosome aneuploidy without putting the 
fetus or the mother at risk for complications.   
Cell-Free Fetal DNA 
It is traditionally taught that the placenta is an impermeable barrier between mother 
and fetus, but it is now known that intact fetal cells and cell-free fetal nucleic acids circulate 
in maternal blood.  Studies have shown that it is possible to use intact fetal cells in maternal 
blood to identify genetic mutations or abnormalities; however intact cells have a long half-
life and could be present from previous pregnancies, and the number of fetal cells in 
maternal circulation is too low to be clinically applied (Bianchi, 2004).  Researchers then 
discovered that cell-free fetal DNA circulates in maternal blood and that these fragments can 
be amplified by polymerase chain reaction (PCR) to identify fetuses with abnormalities (Lo 
et al., 1997).  Since it is estimated that the half-life of cell-free fetal DNA is 16.3 minutes, a 
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previous pregnancy would not affect the results of another (Lo et al. 1999).  After this 
discovery, non-invasive tests were developed to determine fetal sex and Rh status (Bianchi, 
2004).  Now the focus has shifted to using the technology to identify fetuses with 
chromosome aneuploidy.   
Methods have been developed to identify fetal DNA within maternal blood and 
assess chromosome dosage (Chiu et al., 2008).  One of the main methods used is massively 
parallel shotgun sequencing (MPSS), which includes the sequencing of the first 36bp of 
DNA segments in maternal plasma and aligning these segments to their chromosome of 
origin.  The sequences for each chromosome are then counted and expressed as a percentage 
of unique sequences mapped to that particular chromosome out of all unique sequences that 
were counted.  A chromosome z-score is tabulated for each chromosome.  If a fetus has an 
aneuploidy, the z-score will be higher for that chromosome than for a euploid fetus (Chiu et 
al., 2008).  Due to the increase in the number of samples per run and potential to decrease 
costs, this new technology appears clinically practical. 
Available Commercial Testing 
The goal of non-invasive prenatal testing (NIPT) is to rival the sensitivity and 
specificity of current invasive diagnostic methods without the risk of complications intrinsic 
to those invasive procedures.  NIPT for Down syndrome became commercially available in 
November 2011, and currently there are multiple laboratories offering the test.  NIPT has 
been validated for use in detecting Down syndrome, Trisomy 18, Trisomy 13, Turner 
syndrome in the presence of a cystic hygroma on ultrasound between 10 and 22 weeks 
gestation (Palomaki et al., 2011; Palomaki et al., 2012; Ashoor et al. 2012; Bianchi et al. 
2012; Norton et al., 2012).  Most commercial labs quote detection rates of 99-100% for 
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Down syndrome, 97-100% for Trisomy 18, and 79-92% for Trisomy 13; FPR <1%.  The use 
of NIPT has been studied in twin gestations; however the sample size was small (Canick et 
al., 2012).   
It has been proposed that NIPT will become the diagnostic standard of care; 
however, the test is still considered a screen at this time.  Palomaki et al. (2011) recommend 
confirmatory invasive diagnostic testing following a positive result.  In addition, they 
estimate that the implementation of NIPT into the current screening practices will lower the 
cost of diagnostic testing and reduce procedure-related losses associated with invasive 
prenatal diagnosis by 96% (Palomaki et al., 2011). 
 
Current Guidelines 
National Society of Genetic Counselors Practice Guidelines, 2012  
 Guidelines from the National Society of Genetic Counselors (NSGC) bring attention 
to the fact that the studies performed so far validate NIPT for use in high-risk populations 
including advanced maternal age, positive screening test, abnormal ultrasound suggestive of 
an aneuploidy, or prior pregnancy resulting in an aneuploidy.  In addition, it is 
recommended that a positive NIPT result is followed by a diagnostic procedure in order to 
confirm the finding.  If NIPT is performed, no further serum screening is necessary (Wilson 
et al., 2012). 
National Society of Genetic Counselors Position Statement, 2012 
NSGC supports NIPT as a screening test for those at increased risk to have a 
pregnancy affected by a chromosome aneuploidy as long as the test is offered with informed 
consent which includes appropriate testing and counseling about the benefits and limitations 
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of NIPT.  It is also the recommendation of NSGC that women who receive a positive NIPT 
result be counseled and given the opportunity to pursue confirmatory diagnostic testing 
(NSGC, 2012). 
International Society for Prenatal Diagnosis Policy Statement, 2011 
The International Society for Prenatal Diagnosis (ISPD) acknowledges that the use 
of NIPT can be helpful for those women at increased risk to have a fetus affected by a 
chromosome abnormality as determined by previously recommended screening methods, 
but does not support utilizing NIPT in low risk pregnancies.  The society also states that 
genetic counseling is needed to discuss benefits and limitations prior to informed consent 
(ISPD, 2011) 
American Congress of Obstetrics and Gynecologists Committee Opinion, 2012 
 ACOG opinion states that patients at an increased risk for aneuploidy can be offered 
NIPT but that cell free fetal DNA testing should not be included in routine screening, nor 
should it be ordered without patient consent and appropriate pretest counseling.  
Additionally, patients with positive results should be referred for genetic counseling and 
offered invasive testing for confirmation (ACOG, 2012).   
 
Study Significance 
The integration of NIPT into clinical practice has the potential to revolutionize 
prenatal diagnosis; however, it also raises some crucial issues for prenatal healthcare 
providers and genetic counselors (GC) alike.  A few studies have been published about 
public attitudes regarding NIPT.  Kooij, Tymstra, and van den Berg (2009) found that 
women feel positively about the possibilities of NIPT, but may not fully understand its 
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impact on their individual pregnancies and the prenatal testing arena as a whole.  Although 
studies are currently underway regarding the attitudes of genetic counselors, none have 
looked at the physicians that will be ordering the testing or referring patients to practitioners 
who do.  Obstetricians and/or gynecologists (OB/GYNs) are in a position to identify those 
women who are at risk and might benefit from this new technology.  It is important to know 
what physicians think of NIPT and how they are integrating this new technology into their 
practice.   
Objective 
Through this study, we aim to evaluate the attitudes of OB/GYNs and how they are 
incorporating the test into clinical practice. 
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MATERIALS AND METHODS 
 
Study Design 
This study was conducted by way of an online questionnaire in order to determine 
the attitudes toward and current utilization of NIPT in the practices of OB/GYNs.  The aims 
of this study were to: 
1. Determine if and how OB/GYNs are using the test in clinical practice. 
2. Determine OB/GYNs attitudes about the test. 
 
Hypothesis 
OB/GYNs are not utilizing NIPT for fetal chromosome aneuploidy in clinical 
practice, and are not comfortable with the testing. 
 
Study Approval 
 The study was approved on June 20, 2012 by the Institutional Review Board at the 
University of Texas Health Science Center at Houston Graduate School of Biomedical 
Sciences (IRB# HSC-MS-12-0330). 
 
Study Population 
 The study population consisted of 5,000 practicing OB/GYNs and maternal fetal 
medicine specialists (MFMs).  The list of physician email addresses and other relevant 
practice information was compiled and verified by SK&A Information Services.  Natera 
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purchased a nation-wide targeted list from SK&A which contains email addresses for 5,000 
practicing OB/GYNs or MFMs who ordered CVS and/or amniocentesis in 2011-2012.   
 
Questionnaire 
 A questionnaire (Appendix A) was created in order to assess a nation-wide sample of 
OB/GYN’s.  A review of the literature did not identify a questionnaire specifically 
evaluating the attitudes toward and utilization of NIPT in the practices of OB/GYN’s.  
Therefore, an instrument was created and reviewed by the committee members through 
several phases to ensure that it was clearly worded and appropriately structured to gather the 
desired information.  Experts within the fields relevant to the questionnaire reviewed the 
survey in order to assess content and validity. 
 A cover letter explaining the nature of the study was included in each survey.  This 
letter served as the consent document (Appendix B).  Through the cover letter, physicians 
were informed of the incentive for the study; a $1 donation would be made to the March of 
Dimes for every completed survey received.  Participation in the survey served as consent. 
 The questionnaire consisted of 22-28 questions (depending on the clinician’s prior 
experience with NIPT) and took less than 15 minutes to complete.  The instrument was 
composed of multiple-choice, yes or no, Likert scale, and short answer questions, as well as 
statement agreements.  There were three main sections: (1) demographics, (2) utilization of 
NIPT in clinical practice, and (3) attitude toward NIPT. 
1. Demographics: This section consisted of 11 questions to ascertain gender, areas of 
certification, years since completing residency, area of practice, practice setting, and 
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number of increased-risk patients seen per week among the respondents.  Questions 
in this section were multiple choice and free response where applicable. 
2. Utilization of NIPT in clinical practice: This section was divided based on the 
utilization of NIPT in clinical practice.  The first question evaluated whether or not 
the participant currently uses NIPT in their practice.  If so, the participant answered 
11 questions evaluating which patients are offered NIPT, what factors play a role in 
offering the test, and how the physician responds to the results of the test.  If the 
participant does not offer NIPT in their practice, he/she answered 4 questions 
regarding what factors influence the decision not to offer the test, how the physician 
would respond if a patient requested NIPT, and if he/she plans on incorporating 
NIPT into their practice in the future.  Questions in this section were multiple choice 
(some limited to one response while others were open to several responses), and free 
response were applicable.   
3. Attitude toward NIPT: This section consisted of 5 questions regarding the overall 
comfort in explaining NIPT to patients, and views on how this new technology might 
change the way we screen for prenatal genetic conditions.  Questions in this section 
were multiple choice, agree/disagree statements, and five point Likert scale to assess 
comfort (very comfortable, somewhat comfortable, neutral, somewhat 
uncomfortable, and very uncomfortable) where applicable. 
At the conclusion of the survey, there was a free response box designed for any comments 
regarding the survey or NIPT in general.  Additionally, after notifying participants that their 
participation in the current study had ended, there was space to leave contact information 
should they wish to be contacted in the future for a follow up study.   
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 The final questionnaire was created in Survey Monkey and included a logistic flow 
allowing for those physicians who do and do not utilize NIPT to follow different paths 
through the survey. 
 
Data Collection 
 An email was sent to all 5,000 physicians on Natera’s purchased list inviting them to 
participate in the study.  The invitation explained the purpose of the study and what was 
involved in participation.  A direct link to the survey was embedded in the body of the 
message and directed the participant to the questionnaire on Survey Monkey.  The email 
invitation was sent from Natera but was linked to the PI’s email address so as to protect 
privacy of the study population.  The survey was sent out in 4 waves, each two weeks apart.  
Data collection began on August 14, 2012 and ended on October 3, 2012.   
 
Statistical Analysis 
 Data collected from the questionnaires was downloaded from Survey Monkey to a 
Microsoft Excel file and analyzed using statistical analysis software program, STATA (v.11, 
College Station, TX).  For our primary analysis, we performed a descriptive analysis to 
describe the population and evaluate the attitudes toward and clinical utilization of NIPT.  A 
secondary analysis of the data was performed after stratifying by various demographic 
factors, current use of the test, and attitudes regarding the test.  A comparison between 
groups was performed using contingency tests (Fisher’s exact test, Chi-squared analysis), 
Mann-Whitney sign-rank, Wilcoxon signed rank, and Kruskal-Wallis tests where 
appropriate.  Linear and logistic regression models were used to assess any linear trends 
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over a series of ordinal categories.  Spearman’s correlation tests were utilized to assess the 
degree of correlation between two continuous variables.  Results with a p-value of less than 
0.05 were considered statistically significant.  The null hypothesis used for all statistical 
analysis was that there was no difference between groups. 
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RESULTS 
 
Survey Response 
 The survey was distributed in four waves; each wave was two weeks apart and 
reached out to the same 5,000 physicians.  After each wave, about 1% of the surveys were 
returned immediately due to invalid email addresses or out-of-office replies.  There were a 
total of 175 responses.  Sixteen participants were not included in data analysis for the 
following reasons: 1) nine participants did not complete more than the demographic 
information of the survey, 2) two participants had IP addresses that matched two other 
respondents and had answered questions similarly to those other respondents indicating that 
he/she was likely the same person, and 3) five additional participants were dropped because 
they were not certified as an OB/GYN.  Of the 175 responses, 159 were used in statistical 
analysis, which resulted in an overall 3.2% response rate. 
 
Part I: Demographics 
 The first set of questions aimed to describe the study population.  Out of 159 
participant physicians, 84 (53%) were female, 79 (50%) were boarded in a subspecialty, 77 
(48%) practiced as an MFM, 140 (88%) practiced in an urban area, and 109 (69%) saw less 
than 25 increased-risk patients per week.  The mean number of years since a physician’s 
residency training was 19.3 with a standard deviation of 8.8.  On average among all 
respondents, 55% of their patient population have private insurance, 35% Medicaid, 1% 
military, and 5% uninsured. Overall, 67% (n=103) of the participants predominantly had a 
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privately insured population, while 29% (n=44) had a patient population that was 
predominantly insured by Medicaid.   
Correlations between demographic variables and whether or not the physician 
currently offers NIPT to his/her patients were evaluated, as well as correlations between 
demographic variables and whether or not the physician is a OB/GYN or MFM (Tables 1 
and 2).  “General OB/GYN,” “GYN only,” and “OB only” were combined to make up the 
group “OBs” when compared to MFMs for analysis.  Proportionately more physicians who 
offer NIPT are boarded in a subspecialty (p=0.006).  Of the respondents that are certified in 
a subspecialty, only 3 were not certified as MFMs (p<0.001).  “MFM” was the most 
commonly reported practice area among physicians offering NIPT compared to “General 
OB/GYN” which was the most commonly reported practice area among physicians not 
offering NIPT (p=0.006).  A predominantly privately insured patient population is more 
common among OBs, whereas MFMs see a higher proportion of predominantly Medicaid 
patients (p<0.001).  Compared to MFMs, OBs see a lower volume of increased-risk patients 
per week (p<0.001). 
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 Offered vs. Did not Offer MFM vs. OB 
 n (%) p-value p-value 
Gender  0.202 0.950 
 Female 84 (53)   
 Male 72 (45)   
 Missing 3 (2)   
Boarded in Subspecialty  0.006 <0.001 
 Yes 79 (50)   
 No 80 (50)   
Practice Area  0.006 <0.001 
 General OB/GYN 72 (45)   
 GYN only 3 (2)   
 OB only 2 (1)   
 MFM 77 (48)   
 Reproductive Endocrinology 1 (1)   
 Other 4 (3)   
Practice Location  0.121 0.143 
 Urban 140 (88)   
 Rural 15 (9)   
 Missing 4 (3)   
Table 1: Demographic Background of Physicians with analysis by whether or not 
NIPT is offered and practice area. 
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 Offered vs. Did not Offer MFM vs. OB 
 n (%) p-value p-value 
Patient Insurance by Practice  0.533 <0.001 
 Predominantly Private 103 (67)   
 Predominantly Medicaid 44 (29)   
 Equally Private or Medicaid 7 (4)   
Increased Risk Patients Per Week  0.187 <0.001 
 Less than 25 109 (69)   
 25-50 45 (28)   
 50-75 2 (1)   
 More than 75 3 (2)   
Table 2: Demographic Background of Patient Populations with analysis by whether or 
not NIPT is offered and practice area. 
 
Part II: Knowledge 
 Participants were given five different patient scenarios and asked to identify which 
scenario represented a patient at an increased-risk for having a pregnancy affected by Down 
syndrome.  One hundred fifty-five (97%) correctly identified an AMA patient as increased-
risk, 158 (99%) correctly identified a patient with a positive quadruple screen as being 
increased-risk, 147 (92%) correctly marked that a patient with an abnormal ultrasound is at 
an increased-risk, and 146 (92%) correctly answered that a patient with a second cousin with 
Down syndrome is not at an increased-risk.  Only 90 (57%) participants correctly identified 
that a patient with a karyotype indicating she is 46, XX t(11:22) is not at an increased risk 
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for having a child with Down syndrome.  In summary, participants were able to identify who 
is at an increased-risk. 
 
Part III: Clinical Practice 
 Each participant was asked whether or not they currently offer NIPT to patients in 
their practice.  This question served as a gateway in the survey; physicians that answered 
“yes” answered a different set of questions than those who answered “no”.  Both sets of 
questions aimed to describe the clinical practices of the physicians in each category.  The 
majority (n=127, 80%) of physicians reported that they currently offer NIPT in their clinical 
practice.  Compared to OB/GYNs, proportionately more MFMs are ordering NIPT for their 
patients (p=0.004). 
Physicians Who Offer NIPT 
 The first group of questions aimed to determine which patients are being offered 
NIPT as well as what factors influence a physician’s decision not to offer the test.  Most 
physicians who offer NIPT will offer the test to their patients who are at increased-risk 
(73%), not sure about invasive testing such as CVS or amniocentesis (72%), or refuse 
invasive testing (69%).  Compared with OBs, MFMs offer NIPT significantly more to these 
subset of patients (p=0.014, 0.002, <0.001, respectively).  OBs are more likely to offer NIPT 
to all pregnant patients as compared to MFMs (p<0.001).  Physicians offering NIPT are 
doing so to over 75% of their increased-risk patients (84%).  Compared to MFMs, OBs 
reported that they offered the test to a higher proportion of their increased-risk patients 
(p=0.044).  Participants were then asked which factor(s) influence their decision not to offer 
NIPT to a patient.  Fifty-seven (45%) indicated they do not offer it when their patient shows 
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a lack of interest, 54 (43%) when the patient cannot afford it or when the test is not covered 
by insurance, 13 (10%) when the physician does not feel it is in the patient’s best interest, 
and three (2%) when they run out of time to discuss it with the patient.  Fifty (39%) 
respondents reported that there was another reason for not offering the test.  These 
individuals indicated that they would not order the test if the patient did not have a risk 
factor, there is concern for another genetic condition for which NIPT does not detect, or a 
patient declines. 
 The next question asked physicians at what point do they order NIPT for their AMA 
patients.  Participants were able to check all of the options that apply to their practice.  Fifty-
four (43%) reported they offer NIPT instead of maternal serum screening if the patient is 
AMA.  Sixty-seven (53%) order NIPT after maternal serum screening results are positive.  
Compared to OBs, MFMs are twice as likely to order NIPT after screening results are 
positive (p<0.001).  Seventy-four (58%) offer NIPT to AMA patients if she declines 
invasive testing.  Compared to OBs, MFMs are also twice as likely to order NIPT if a patient 
declines invasive testing (p<0.001).  Seventy-six (60%) offer NIPT in order to help a patient 
decide if they want to pursue invasive testing.  Physicians were then asked what detection 
rate they quote their patients when discussing the option of NIPT.  Most physicians quote 
the accuracy of NIPT in detecting Down syndrome as greater than 89%; 71 (45%) quote 99-
100%, and 42 (26%) quote 90-98%.   
The next group of clinical practice questions for participants who offer NIPT was 
aimed to describe what physicians do with a positive NIPT result.  Most participants 
indicated that their first recommendation after a positive NIPT result is invasive testing.  
MFMs are more likely than OBs to offer invasive testing, whereas OBs are more likely to 
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refer patients to a specialist following a positive result (p<0.001).  When asked if the 
physician offers a CVS/amniocentesis to confirm the NIPT result, most physicians answered 
yes; however, MFMs are more likely to offer an invasive procedure following a positive 
result compared to OBs (p=0.029).  Of note, physician participants offer invasive testing to 
the majority of their increased-risk patients even without a positive NIPT.  Eighteen 
participants answered that whether or not they would offer invasive testing after a positive 
NIPT result would depend on factors such as ultrasound findings and patient preferences.  
Three of the 18 indicated that they would refer to an MFM at that point.  MFMs are more 
likely to refer to a GC prior to ordering the test, whereas OBs are more likely to refer after a 
receiving a positive result (p<0.001). 
The last two questions for physicians that offer NIPT to their patients asked what 
they do with the two populations for whom the testing is not currently validated, women 
who are pregnant with multiples, and low-risk women.  Fifty-nine (37%) physicians 
reported that they do offer NIPT to patients who are pregnant with multiples, fifty-three 
(33%) reported that they would not, and forty-seven (30%) did not answer this question.  
Physicians that would not offer the test to this type of patient indicated their concern about 
the accuracy and validity of the test and the need for more data, as well as the fact that the 
affected fetus cannot be identified using this method.  Forty-five percent of participants 
would order NIPT on a low-risk patient if she requested it.  Compared to MFMs, OBs are 
more likely to order NIPT if a low-risk patient asked for it (p<0.001).  Twenty-nine (23%) 
physicians reported that their decision to offer the test for a low-risk patient would depend 
on her understanding the benefits and limitations of the testing in a low-risk population, 
what her other options are, and what the test will cost. 
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Physicians Who Do Not Offer NIPT 
 The questions for physicians who do not currently offer NIPT to their patients were 
aimed to determine what factor(s) influence their decision not to offer the test, what the 
physician would do if a patient requested the test, and whether or not the physician plans on 
incorporating NIPT into their practice in the future.  Fourteen (23%) do not feel there is 
enough published data on NIPT, 14 (23%) identify that there were no published practice 
guidelines at the time from their professional society, 12 (19%) identify cost and/or lack of 
insurance coverage as a factor, six (10%) report that their institution and/or colleagues are 
not utilizing this test, three (5%) note a lack of interest from their patients, three (5%) 
express that the test is not convenient, and one (2%) participant felt that there is not enough 
time to discuss this new option with patients.  Nine (15%) chose “other.”  These physicians 
indicated that they prefer to start with maternal serum screening, rely on others such as 
MFMs to offer this testing, or that the population of patients they see would not benefit from 
this test.  If an increased-risk patient requested NIPT, 18 (56%) would order it, one (3%) 
would not, and 13 (41%) would refer the patient to an MFM or genetic counselor.  
Significantly more MFMs are willing to order NIPT if requested by an increased-risk patient 
than OBs (p=0.009).  If a low-risk patient requested NIPT, 10 (32%) physicians would order 
it, 7 (23%) would not, and 14 (45%) would refer to an MFM or genetic counselor.  MFMs 
are more likely to not order NIPT if requested by a low-risk patient compared to OBs, 
whereas OBs are more likely to refer those patients to an MFM and/or genetic counselor 
(p=0.002).  When asked if the physician plans to incorporate NIPT into his/her practice in 
the future, 22 (69%) answered yes and 10 (31%) answered no.  Those participants that 
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answered no did so because they would refer their patients to an MFM or genetic counselor, 
it is not standard of care, or there is not enough data for low-risk populations. 
Part IV: Attitudes 
 When asked how comfortable they are explaining NIPT to patients, most physicians 
indicated that they were very comfortable (43%) or somewhat comfortable (31%).  
Responses show that physicians that offer NIPT are more comfortable explaining the test to 
their patients than those who do not order it (p<0.001).  Additionally, physicians who could 
correctly identify that women with an abnormal ultrasound were at an increased-risk to have 
a child with Down syndrome were more comfortable explaining NIPT to patients than those 
physicians who could not (p=0.010). 
 All participants answered the following series of questions by indicating whether 
they agree or disagree with the following statements (Table 3).  When asked to evaluate the 
statement about NIPT making prenatal diagnosis more complicated, more OBs disagreed 
with this statement than MFMs (71% vs. 49%, p=0.001).  Proportionately more OBs think 
NIPT will replace invasive procedures than MFMs (67% vs. 54%, p=0.018).  Physicians that 
do not offer NIPT disagreed more with the statement about more studies being needed to 
establish the clinical validity and utility of NIPT than physicians that do offer it (88% vs. 
66%, p=0.046).  When asked to evaluate whether NIPT is going to simplify prenatal 
diagnosis, proportionately more OBs agree with this statement than MFMs (63% vs. 44%, 
p=0.011).  More MFMs disagreed with the statement saying NIPT should currently be 
offered to low-risk patients than OBs (75% vs. 36%, p<0.001).  When asked whether they 
think NIPT will replace maternal serum screening in the future, proportionately more MFMs 
disagree with this statement than OBs (29% vs. 13%, p=0.017).  
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Statement Agree, n (%) 
I think NIPT is pointless. 0 (0) 
NIPT is leading us down a slippery slope. 16 (10) 
I feel NIPT is just a way for labs to make money. 3 (2) 
NIPT is going to make prenatal diagnosis more complicated. 49 (31) ** 
I think NIPT will replace invasive procedures. 95 (60) ** 
As practitioners, we need more information/education about the test/technology. 125 (79) 
More studies are needed to establish clinical validity and utility. 112 (70) * 
NIPT is going to revolutionize prenatal diagnosis. 115 (72) 
NIPT is going to simplify prenatal diagnosis. 85 (53) ** 
NIPT should currently be offered to patients not at increased risk. 54 (34) ** 
I think NIPT will replace maternal serum screening in the future. 112 (70) ** 
* Significant difference between physicians that offer NIPT and those who do not  
** Significant difference between MFMs and OBs 
Table 3: Attitude Statements with analysis by whether or not NIPT is offered and 
practice area. 
When asked whether the physicians consider NIPT to be a screening test or 
diagnostic test, 86 (54%) consider it a screen, 33 (21%) consider it a diagnostic test, 15 (9%) 
consider it to be neither a screening nor a diagnostic test, and 13 (8%) are not sure how to 
classify it.  Compared to MFMs, OBs are more likely to consider NIPT a diagnostic test 
(p=0.024). 
The aim of the last two questions was to determine how the participants viewed the 
future of NIPT.  When asked how the introduction of NIPT will affect their clinical practice, 
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121 (76%) participants felt it would reduce the number of invasive procedures performed, 
21 (13%) were not sure how it would affect their practice, and 4 (8%) reported that they did 
not think NIPT would affect their practice.  Proportionately more physicians that do not 
offer NIPT are unsure as to how the introduction of the test will affect their practice as 
compared to those who do offer NIPT to their patients (p=0.038).  One hundred (63%) 
physicians reported that they think NIPT will eventually become the standard of care when 
evaluating a pregnancy for chromosome aneuploidy, 14 (9%) do not think it will be standard 
of care, and 33 (21%) are unsure.  Proportionately more physicians that do not offer NIPT 
are unsure as to whether or not NIPT will become the standard of care for the evaluation of 
chromosome aneuploidy as compared to those who do offer NIPT to their patients 
(p=0.007). 
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DISCUSSION 
 
 The use of invasive prenatal testing (NIPT) has grown since it became clinically 
available in the fall of 2011.  Additional laboratories have introduced their own version, 
costs have decreased, insurance coverage has improved, and public awareness has increased.  
In the absence of professional society guidelines, the purpose of this study was to determine 
if and how OB/GYNs are utilizing this new technology in detecting chromosome aneuploidy 
in their patients as well as how the physicians view the introduction of this new test.  This is 
the first nation-wide study looking at the utilization of and attitudes toward NIPT among 
OB/GYNs and MFMs in the detection of fetal aneuploidy. 
 
Demographics 
 The study cohort consisted of physicians who had ordered a CVS or amniocentesis in 
2011-2012 and self-identified as being certified as OB/GYNs.  Fifty-three percent of our 
respondents were females.  Our study population reported a mean number of 19.3 years 
since completion of residency.  Forty-eight percent of our physicians practice primarily as 
MFMs and 45% practice in a general OB/GYN capacity.  Nine percent of our physicians 
reported practicing in an area other than general OB/GYN or MFM, including GYN only, 
OB only, gynecologic oncology, reproductive endocrinology, reproductive genetics, prenatal 
genetics, and urologic gynecology.  According When compared to the demographic 
distributions reported in the 2008 Socioeconomic Survey of ACOG Fellows (2008), our 
study sample is not representative of the current ACOG membership with regards to gender, 
years in practice, and specialty.  However, since our participants were pulled from a likely 
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biased population of physicians who had recently ordered invasive testing, differences 
between this study’s population and the ACOG Fellows are not surprising.  
 
Knowledge 
 ACOG, NSGC, and ISPD recommend that NIPT be offered only to those women 
whose pregnancy is at an increased-risk for chromosome aneuploidy (ACOG, 2012; NSGC, 
2012; ISPD, 2011).  One goal of the study was to determine if physicians could correctly 
identify patients who were at an increased-risk to have a pregnancy affected by a 
chromosome aneuploidy.  Participants were given five patient descriptions and instructed to 
mark those who were at an increased risk to have a child with Down syndrome.  One of the 
patient descriptions indicates that the woman has a second cousin with Down syndrome.  
For some labs offering NIPT, a “family history” of Down syndrome is sufficient to classify 
a pregnancy as “increased-risk”; however, having one distant relative, like a second cousin, 
with Down syndrome does not increase a couple’s risk for having a child with Down 
syndrome nor any other chromosome aneuploidy.  Ninety-two percent of our physician 
participants correctly identified that this description is not enough to put the patient in the 
increased-risk category.  The final patient description required physicians to indicate 
whether or not a woman with a balanced translocation between chromosomes 11 and 22 was 
at an increased risk to have a baby with Down syndrome.  Since this translocation does not 
involve the 21st chromosome which is the one responsible for causing Down syndrome, a 
woman who is 46, XX t(11:22) is not at an increased risk to have a pregnancy affected by 
Down syndrome.  However, 10% of our participants considered this patient at an increased-
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risk.  It could be that the physicians do not understand the genetic etiology of Down 
syndrome and/or how balanced translocations can cause genetic abnormalities in offspring.   
 Overall, the majority of our participants were able to correctly identify which women 
were at an increased-risk to have a child with Down syndrome.  Based on this finding, most 
physicians are capable of identifying those women who could benefit from NIPT.  Sayres et 
al. (2011) showed that 85% of their physician respondents did not report having a high level 
of knowledge about cell-free fetal DNA testing.  Although our study did not address this 
question directly, our results indicate that physicians could indeed have a sufficient level of 
knowledge to order the testing for their patients.  Whether or not participants interpret test 
results correctly, is not addressed by this study.  The discrepancy between the results from 
the Sayers study and ours could be explained by the time lapse between the two.  Sayers et 
al. (2011) collected their data in October of 2010, one year before the launch of NIPT for the 
detection of chromosome aneuploidy.  In 2010, cell-free fetal DNA testing was available 
only for Rh group blood group typing and fetal sex determination. 
 
Clinical Practice 
One aim of the current study was to determine if and how OB/GYNs are utilizing 
non-invasive prenatal testing (NIPT) in their clinical practice.  To address the first part of 
the study aim, physician participants were asked whether or not they currently offer NIPT to 
their patients.  Most physicians reported that they do offer NIPT to their patients.  In order to 
address the second part of the study aim, physicians were asked a different set of questions 
depending on whether or not they currently offer NIPT to their patients.  The participants 
who offer NIPT were asked questions about how they use the testing in their practice, 
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whereas the participants who do not offer NIPT were asked questions about their reasoning 
for not offering the test and intention to incorporate it into their practice in the future.   
Factors Influencing Decisions 
 At the time of this study, the use of NIPT for the detection of chromosome 
aneuploidy had been validated for the increased-risk population (Palomaki et al., 2012; 
Sparks et al., 2012).  Published statements from NSGC and ISPD further supported the 
utilization of NIPT for women at an increased risk for chromosome aneuploidy (NSGC, 
2012; ISPD, 2011).  A study by Sayres et al. (2011) suggests that providers of healthcare in 
obstetrics will follow the guidance of their professional societies when deciding whether or 
not to offer NIPT.  Our study shows that physician practices regarding NIPT are congruent 
with the literature and professional society opinions available at the time of data collection.  
Physicians are ordering NIPT for their increased-risk patients and are doing so for those 
patients who are undecided about or have refused invasive testing options.  Patients refuse 
may refuse invasive testing due to the fact that they are not comfortable with the risk of 
miscarriage; however some patients refuse testing because they do not want more 
information about the genetic condition of their unborn child.  It is important that physicians 
enquire further about a patient’s reason for declining invasive testing before offering NIPT 
as an alternative.  For those physicians who are offering NIPT to their patients, the most 
common factors influencing them to not offer NIPT were a lack of interest from the patient 
and an inability of the patient to afford it.  The list price for the test when first launched was 
nearly $2,000.  Over time, more competition and acceptance by insurance companies has 
decreased the patient’s out-of-pocket cost significantly.  It may be that as time passes, this 
factor will hold less importance in decision making.   
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 Although physicians who do not offer NIPT also indicated that cost and/or lack of 
insurance coverage plays a role in their decision not to offer the testing, the most common 
factors influencing their decision were that there is not enough published data on NIPT and 
that there are no published practice guidelines from their professional society.  Even though 
there have been several studies published about the effectiveness of NIPT in detecting 
chromosome aneuploidy, the technology is new and not well established.  Furthermore, 
many of the studies have been conducted with assistance from the laboratories offering the 
testing, which may lessen the effect of their findings for some physicians.  Additionally, the 
group of physicians that do not offer NIPT might have been waiting for a specific ACOG 
guideline before making a change in their practice.  Our findings also show that MFMs who 
do not currently offer NIPT to patients are more likely to order it if an increased-risk patient 
requests it compared to OBs, indicating that they recognize the test’s utility but do not see 
the need to offer it to their patients at this time.  Since the completion of data collection, 
ACOG has released a committee opinion about NIPT.  The document supports the use of 
NIPT for increased-risk women who receive adequate pretest counseling, and recommends 
that women with a positive result should be referred for genetic counseling and confirmatory 
invasive testing (ACOG, 2012).  This ACOG guideline is likely to affect the practices of 
OBs and MFMs alike with physicians modifying their current practices and/or attitudes 
about testing.  Some physicians/institutions will likely begin offering the test with this 
additional support. 
Detection and Diagnosis 
 The literature, as well as the two laboratories offering NIPT at the time of data 
collection, quoted the detection rate for Down syndrome as being above 99% (Palomaki et 
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al., 2012; Sparks et al., 2012).  Seventy-one percent of our physician respondents tell their 
patients the detection rate of NIPT for Down syndrome is greater than 89%.  Forty-five 
percent tell their patients the detection rate is at least 99%.  For Down syndrome, the 
detection rate of NIPT is very similar to that of the available invasive procedures.  It may be 
that they are not comfortable quoting such a high detection rate for such a new test being 
marketed as a screening tool.  The literature, the laboratories offering testing at the time of 
this study, and NSGC practice guidelines recommend confirming a positive NIPT result 
with a diagnostic invasive procedure such as a CVS or amniocentesis (NSGC, 2012; 
Palomaki et al., 2011).  Most of our respondents reported that they offer an invasive 
procedure to confirm a positive NIPT result.  In fact, confirmation via invasive diagnostic 
testing is the first recommendation for 59% of our respondents when the NIPT indicates an 
affected fetus.  This is not surprising given that the majority of our respondents offer 
invasive procedures to a high percentage of their increased-risk patients in general.  For 
those participants that do not always offer an invasive procedure to their patients following a 
positive result, many reported that their decision to offer a diagnostic procedure would 
depend on ultrasound findings.  It seems that if ultrasound findings supported the NIPT 
result, physicians would feel comfortable enough to not follow up with an invasive 
procedure prior to discussing pregnancy options with the patient. 
Additional Patient Populations 
 At the time of data collection for this study, NIPT testing was validated, 
recommended, and marketed only for women who were at an increased-risk of having a 
baby with a chromosome aneuploidy; however, 45% of our participants who currently offer 
NIPT to patients would order it for a low-risk woman if she requested the testing compared 
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to 32% of physicians who do not currently offer NIPT.  Regardless of whether or not they 
currently offer NIPT to their patients, MFMs in our study were more likely to say no to a 
low-risk patient requesting NIPT, indicating that they are more selective than OBs when 
ordering the testing.  Yotsumato et al. (2012) surveyed healthcare professionals in Japan and 
reported that 36% of their participants felt that all women should be allowed to undergo the 
test if they desire.  Our study participants emphasized that when a low-risk woman requests 
NIPT, she should have a good understanding of the benefits and limitations, what all of her 
options are, and what the test might cost her financially.  Many physicians, especially OBs, 
indicate that a patient should be referred to an MFM and/or genetic counselor to address 
these issues. 
 During the data collection of this study, Canick et al. (2012) published a paper 
showing that the MPSS technology utilized in NIPT can reliably detect Down syndrome in 
women with high-risk twin gestations; however only 25 twin and two triplet pregnancies 
were evaluated.  It is unclear as to whether or not this study population is enough to validate 
NIPT usage in multiple gestations.  The issue is further complicated in that NIPT in multiple 
gestation pregnancies is limited, as is maternal serum screening, because the affected fetus 
cannot be identified by this method alone.  Without significant ultrasound findings, an 
invasive procedure would be necessary to confirm which baby was the affected one.  At the 
time of this study, the ISPD was the only professional society to mention multiple gestation 
pregnancies in their position statement.  The society noted that more studies were needed to 
validate its use in this population (International Society of Prenatal Diagnosis, 2011).  Our 
study showed that about one-third of physicians would not order NIPT on a patient who was 
pregnant with multiples, about one-third would, and about one-third of our participants did 
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not answer this question.  The authors wonder if so many participants did not answer this 
question because they were not sure if they should offer NIPT to multiples, or if they had 
not come across this situation at the time of this study. 
MFMs vs. OBs 
 Among the physician participants who offer NIPT to their patients, this study found 
differences between the clinical practices of MFMs and general OBs regarding NIPT.  First, 
although most of our physician participants offer NIPT to their patients, more MFMs are 
offering the test compared to OBs.  When the test is offered, MFMs offer it specifically to 
help increased-risk patients decide whether or not to pursue invasive testing.  However, most 
OBs in our population felt that NIPT should be offered to low-risk patients.  MFMs also 
report that they primarily order the test after maternal serum screening results come back 
positive.  This finding could be due to the fact that many patients are not referred to an 
MFM until after the results of a patient’s maternal serum screen, drawn by the OB, are 
positive.  MFMs tend to turn more to invasive testing after a positive result, whereas OBs 
tend to refer their patients to an MFM and/or genetic counselor to discuss the results and 
available options.  When referring patients to genetic counselors, MFMs generally do so 
before ordering NIPT whereas OBs primarily refer to specialists after the results are 
positive.  MFMs are certified primarily as OB/GYNs but have completed more focused 
training in high-risk pregnancy situations, including women suspected of being at an 
increased-risk for having a baby with a chromosome aneuploidy.  For this reason, it is not 
surprising that their practices would differ from that of OBs regarding the utilization of 
NIPT.  For example, some OBs may feel comfortable managing a pregnancy at increased-
risk for aneuploidy, whereas others may not.  Others may prefer to not perform invasive 
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procedures and refer their patients to specialists.  Due to the nature of their practice, MFMs 
are usually somewhat familiar with genetic testing; they may be in a position to better 
understand the technology including its benefits and limitations, and therefore are likely to 
be more selective when ordering the test. 
 
Attitudes 
Comfort 
 Our physician participants, especially those who offer NIPT, report that they are 
comfortable explaining NIPT to their patients.  This finding is supported by the fact that 
respondents who do not offer NIPT identified a need for more information about the testing 
as a major factor in their decision to not offer it, as well as a need for more studies to 
establish clinical validity and utility. The ability to identify increased-risk patients is also 
associated with a high level of comfort explaining the test to patients.  Specifically, 
physicians that associate an abnormal ultrasound with an increased-risk for Down syndrome 
are more comfortable explaining the testing to their patients. This implies that physicians 
with a higher level of knowledge about NIPT could be more comfortable explaining the 
testing to patients, and possibly more likely to order the testing.  However, more knowledge 
measures would be needed in order to verify this possibility. 
Screening or Diagnostic Test? 
NIPT has been validated and marketed as a new technology in order to screen 
pregnancies at increased-risk for chromosome aneuploidy; however, the test’s detection rate 
for Down syndrome is greater than 99%, which approaches the accuracy of current invasive 
diagnostic procedures.  About half of our study participants classified NIPT as a screening 
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test; however 17% consider NIPT to be neither a screen nor diagnostic, or are unsure as to 
how to classify it.  OBs more often identified NIPT as a diagnostic tool.  These findings 
indicate that physicians do not know how to classify the test.  Additionally, some physicians 
may not consider NIPT as a diagnostic tool due to the fact that it only tests for a limited 
number of conditions.  Those OBs that are considering NIPT a diagnostic test may be doing 
so more hastily than other physicians.  NIPT may be considered a diagnostic test in the 
future; however at this time there are not enough studies to classify it as such. 
Although NIPT is a new method for screening AMA women to aid providers in 
personalizing risk, when considering their AMA patients, more of our participants indicated 
they offer NIPT after a positive maternal serum screening result as opposed to using the test 
as a replacement for first or second trimester screening.  NIPT was developed in order to 
provide a new means of prenatal diagnosis without the risk of miscarriage, but at the time of 
this study NIPT is not considered diagnostic but rather a screening tool.  However, it appears 
that when physicians are utilizing this technology, they are doing so as a way of getting 
more detailed information after less reliable screening methods rather than replacing them. 
Future 
 Palomaki et al, (2011) proposed that complete uptake of NIPT by high-risk women 
would decrease the amount of invasive procedure-related losses due to the fact that less 
invasive procedures would be necessary to detect almost all cases of Down syndrome.  Our 
participants agree that NIPT will affect their practice by reducing the number of invasive 
procedures performed.  Within our study population, more OBs felt that NIPT would replace 
invasive procedures compared to MFMs.  A reduction in invasive procedures may decrease 
the amount billed by physicians for those procedures which could impact clinic income.  
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MFMs care for more increased-risk patients than OBs and also follow women whose 
pregnancies at increased-risk of complications for a variety of reasons.  Overall, NIPT may 
replace invasive procedures, but MFMs are likely to still have a reason to perform them than 
general OBs, due to the nature of their patient population.  Of note, both MFMs and OBs felt 
that NIPT would eventually replace maternal serum screening; however, OBs agreed more 
strongly with this idea.  OBs seem to feel that NIPT covers both maternal serum screening 
and invasive procedures at the same time.  Additionally, study respondents feel that NIPT 
will simplify the world of prenatal diagnosis rather than make it more complicated; 
however, OBs agreed with this idea more than MFMs.  Since more MFMs are ordering the 
testing than OBs, it may be that MFMs see how NIPT might affect the bigger picture of 
prenatal diagnosis.  For example, MFMs might be thinking ahead to how the technology 
might expand to other genetic conditions and what affect that may have on their practice. 
The physicians who did not offer NIPT at the time of this study were unsure as to 
how the test might affect their practice.  It is reasonable to assume that this feeling could be 
influencing their decision not to offer the testing to their patients.  The majority of the 
physicians who do not currently offer NIPT reported that they plan to do so in the future.  It 
may be that the published opinion from ACOG as well as more research about the testing 
and potential effects on prenatal diagnosis would increase comfort with offering NIPT.  
Physicians who do not plan to incorporate NIPT into their clinical practice report that they 
refer their patients to an MFM and/or genetic counselor.  These respondents would likely 
continue to do so despite additional information and publications on NIPT. 
 Currently, maternal serum screening and CVS/amniocentesis are the standard of care 
for evaluating for chromosome aneuploidy.  However, the majority of the study population 
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feels that NIPT will eventually become the standard of care.  Physicians that do not offer 
NIPT are most likely to be unsure as to whether or not NIPT will become the standard of 
care for evaluating a pregnancy for chromosome aneuploidy.  This is likely related to the 
finding that physicians that do not offer NIPT are also unsure as to how NIPT will affect 
their practice.  Overall, those that don’t offer NIPT are unsure about how the test might 
affect them, which is likely influencing their choice not to offer the testing at this time, and 
is supported by their desire for more validation and recommendations from their 
professional societies. 
 
Additional Factors to Consider 
Since NIPT became clinically available in November 2011, much has changed.  
Prior to data collection for this study, NIPT for trisomies 21, 18, and 13 was offered by three 
clinical laboratories, one of which reported the presence or absence of Y chromosome 
material, another accepted patients with Medicaid and/or CHIP insurance.  Additionally, 
ISPD and NSGC had published position statements on the testing and its utilization in 
detecting fetal chromosome aneuploidy.  During the period of data collection, one more lab 
began reporting on the presence or absence of Y material.  After data collection was 
complete for this study, a fourth laboratory began offering the test utilizing a different 
method, two labs began testing for sex chromosome abnormalities, and an additional lab 
began reporting on the presence of Y material.  Additionally, NSGC published a white paper 
on the clinical use of NIPT and the American College of Obstetricians and Gynecologists 
(ACOG) published a committee opinion on NIPT for fetal aneuploidy (ACOG, 2012).  It is 
unclear how these changes might affect the results of this study; however, the authors 
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suspect that ACOG’s committee opinion is likely to have an impact, especially on 
physicians who were previously not offering the testing. 
 
Strengths and Limitations 
There have a been few studies examining attitudes of physicians regarding the future 
incorporation of NIPT (Sayres et al., 2011; Yotsumato et al., 2012).  However, since NIPT 
became clinically available in the fall of 2012, there have been no studies, to our knowledge, 
addressing the utilization of and attitudes toward this new technology among physicians 
who could order the testing for their patients.  Through the clinical practice portion of this 
study, we were able to describe how OB/GYNs and MFMs are incorporating NIPT into their 
clinical practice.  Additionally this section enabled us to better understand why physicians 
may not utilize this testing with their patient populations.  This study evaluated the attitudes 
of OB/GYNs and MFMs regarding NIPT as well as the attitudes of physicians who do and 
do not offer the test to their patients. 
 Although this study queried physicians across the United States, our response rate 
was only 3.18%.  This response rate is lower than similar studies examined for this project; 
however, the total number of respondents is higher making our study the largest, most 
comprehensive study on the topic of NIPT to date. 
Due to the low response rate and small sample size, there was not an adequate 
amount of respondents to stratify by multiple variables.  For example, outside of the general 
OB and MFM sub-specialties, there were very few participants in order to determine if their 
clinical practice and attitudes differed from other groups.  In addition, the study sample may 
not be representative of the greater ACOG fellowship, especially in practice area.  This 
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difference may be due to the way this study population was selected from a group of 
physicians that had ordered an invasive procedure in 2011-2012.  In general, MFMs order 
more invasive procedures due to the nature of their practice, and therefore would be more 
highly represented in our study population than that of ACOG’s fellowship.  Furthermore, 
all of the variables measured in this study were based on self-reported information and may 
not represent actual practice.  This study is limited by a selection bias in that the 
questionnaire was emailed to a select group and may not represent the target population as a 
whole.  Physicians that knew more about NIPT and/or utilized the test in their clinical 
practice might have been more likely to participate in the study.  Another limitation to this 
study is that the questionnaire was not adapted from an established tool; it was created by 
the authors and piloted to committee members.  There was no reliability or internal validity 
tests performed on the questionnaire prior to its utilization in the study population. 
 
Final Conclusions and Future Studies  
 This study shows that most physicians are offering this new, non-invasive 
technology to their patients, and that at the time of data collection their practices were 
congruent with the literature and available professional society opinions.  Physicians did 
indicate, however, that they would deviate from these guidelines if a patient fully understood 
the benefits and limitations of the testing.  Those physicians who do not offer NIPT to their 
patients indicated that they needed more literature on the topic as well as instructive 
guidelines from their professional societies.  Since then, ACOG has published a committee 
opinion on the matter, likely providing this group with what they needed to feel comfortable 
offering the test as an option to their patients.  Additionally, our study shows that the 
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practices and attitudes of MFMs and OBs differ somewhat, which may be a result of their 
differing patient populations and area of expertise.  The respondents feel that the 
incorporation of NIPT will change their practices by lowering the amount of invasive 
procedures, possibly replacing maternal serum screening, and that it will simplify prenatal 
diagnosis.  However, those physicians who do not offer NIPT to their patients are not quite 
sure how the test will affect their clinical practice.  This may be an underlying reason as to 
why they are not offering it. 
 From this study we learned much about how physicians are incorporating this new 
technology into their practice and how they feel about the addition to the plethora of 
available prenatal tests.  This knowledge gives us insight as to how to best move forward 
with the quickly changing field of prenatal diagnosis.  It is likely that in the future we will be 
able to diagnose single-gene disorders in a similar fashion.  Genetic professionals need to be 
aware of what the ordering physicians are doing as we encounter more and more of their 
patients.  This study also gives us an idea of how we can better serve our patients by 
properly supporting and educating their physicians.   
 Although this study adds to the current literature about the utilization of NIPT, there 
is much to be learned about implementing this technology.  The environment surrounding 
NIPT will continue to evolve with additional literature, improvements of technology, and 
the inclusion of more laboratories offering the test.  Our study captured physician attitudes 
and practices at one moment in time, but this may have changed since the publication of 
ACOG’s committee opinion.  Additional studies may address these changes by examining 
whether or not the abundance of choices in testing labs and methodology affects their 
practice as well as their preferences.  It would also be beneficial to replicate our study with a 
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larger sample size.  Since there were many differences between OBs and MFMs, a focused 
study on OBs may add much to the literature as well.  Our study did not focus on the 
knowledge of physicians regarding NIPT.  A future study might examine what they 
understand about the technology, and whether or not physicians truly understand the benefits 
and limitations of NIPT.  
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Appendix A 
 
Part I: Demographics 
What is your gender? 
 Male 
 Female 
 
How many years has it been since the completion of your primary residency?  
_______________ 
 
Are you board certified in Obstetrics and Gynecology? 
 Yes 
 No 
 
Are you boarded in any sub-specialty? 
 No 
 Yes. Please indicate which one(s) below: 
i. Gynecologic Oncology 
ii. Maternal Fetal Medicine 
iii. Medical Genetics 
iv. Reproductive Endocrinology 
v. Urogynecology 
vi. Other: ___________________ 
 
Which of the following best describes your area of practice? (check one) 
 General Obstetrics and Gynecology 
 Gynecology only 
 Obstetrics only 
 Gynecologic Oncology 
 Maternal fetal Medicine 
Reproductive Endocrinology 
Urogynecology 
Other: __________________ 
 
What is your primary practice setting? (choose all that apply) 
 Private Practice 
 Hospital-based 
 Academic Institution/University Medical Center 
 Other ________________ 
 
Where is your practice located? 
 STATE 
 
Is your practice mostly: 
 Urban 
 Rural 
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Regarding insurance coverage, what proportion of your patients are: 
 ___ Privately insured 
 ___ Medicaid 
 ___ Military (Tricare) 
 ___ Uninsured (Self-pay) 
 
In your practice, who do you consider at increased risk for Down syndrome? (check all that 
apply) 
a. A patient who is advanced maternal age (>35) 
b. A patient with an abnormal quad screen for Down syndrome 
c. A patient whose fetus has a heart defect on ultrasound 
d. A patient whose second cousin has Down syndrome 
e. A patient who is 46, XX t(11:22) 
 
On average, how many patients do you see per week with an increased risk for a 
chromosome aneuploidy? 
a. Less than 25 
b. 25-50 
c. 50-75 
d. More than 75 
 
Part II: Clinical Practice 
1. Do you offer non-invasive prenatal diagnosis (NIPT) with patients in your practice?  
Y____ N____ 
If yes, answer questions 2-12.  If no, answer questions 13-16. (The answer to this 
question determines the track of questioning the participant will answer.  Survey 
Monkey allows for this set up.) 
 
2. To which patients do you offer NIPT: (check all that apply) 
a. Patients at increased risk  
b. Patients who request it 
c. Patients who have an indication for invasive prenatal diagnosis but are not sure 
they want to do it 
d. Patients who have an indication for invasive prenatal diagnosis but refuse 
invasive testing 
e. All pregnant patients 
f. Other: (please list)_____________________________________________ 
 
3. To what percentage of your increased risk patients do you offer NIPT?  
a. 90-100% 
b. 75-90% 
c. 50-75% 
d. 25-50% 
e. 10-25% 
f. <10% 
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g. None 
 
4. For those patients that you do not order NIPT, what factors influence your decision 
not to offer it? (check all that apply) 
a. Lack of interest from my patient 
b. My patient cannot afford it/it is not covered by their insurance 
c. I run out of time discussing options with my patient 
d. I feel it is not in my patient’s best interest 
e. Other (please elaborate)_______________________________ 
 
5. To what percentage of your increased risk patients do you offer invasive testing 
(CVS, amniocentesis)?   
a. 90-100% 
b. 75-90% 
c. 50-75% 
d. 25-50% 
e. 10-25% 
f. <10% 
g. None 
 
6. If a patient is advanced maternal age, do you order NIPT: (check all that apply) 
a. Instead of first trimester or quad screens 
b. After serum screen results are positive 
c. If a patient declines CVS/amniocentesis 
d. To help a patient decide if they want to pursue CVS/amniocentesis 
 
7. What do you tell your patients the accuracy is for NIPT in detecting Down 
syndrome? 
a. 99-100% 
b. 90-98% 
c. 80-89% 
d. 70-79% 
e. <70% 
 
8. Do you offer invasive diagnostic testing (CVS, amnio) to confirm abnormal NIPT 
results? 
a. Yes 
b. No 
c. It depends   Comments: 
 
9. Do you order NIPT on multiple gestations? 
a. Yes 
b. No  Why not? __________________________________ 
 
10. If a patient has a positive NIPT result, what is your first recommendation? (Choose 
the best answer) 
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a. I offer CVS/amniocentesis. 
b. I perform a targeted ultrasound. 
c. I refer the patient to a specialist, such as an MFM or genetic counselor. 
 
11. With regards to NIPT, when do you refer patients to a genetic counselor? 
a. Prior to ordering the test. 
b. Only when patients have a positive result. 
c. I do not refer to genetic counselors for NIPT. 
 
12. If a low-risk patient asks for NIPT, would you order it?  Yes_____ No_____ 
Depends_______   Comments:  
 
13. What factors influence your decision to not use NIPT (check all that apply)?  
a. Not enough published data regarding detection rates, effectiveness, etc.  
b. Lack of interest from my patients 
c. My colleagues and/or institution are not supportive of this test and/or are not 
using it 
d. No published position papers or practice guidelines from my professional 
society(ies) about this testing 
e. Not convenient (i.e. not enough local blood draw sites for my patients to 
access this testing) 
f. Cost and/or lack of insurance coverage for my patients 
g. Not enough time to discuss NIPT with the patient 
h. Other (please elaborate)_______________________________ 
 
14. If an increased-risk patient asks for NIPT, would you order it?   
a. Yes 
b. No 
c. I would refer them to an MFM or genetic counselor. 
 
15. If a low-risk patient asks for NIPT, would you order it?   
a. Yes 
b. No 
c. I would refer them to an MFM or genetic counselor. 
 
16. Do you plan on incorporating NIPT into your practice in the future? 
a. Yes 
b. No  Why not? _____________________________ 
 
Part III: Attitudes 
1. How comfortable are you explaining NIPT to your patients? 
5 4 3 2 1 
Very 
comfortable 
Somewhat 
comfortable 
Neutral Somewhat 
uncomfortable 
Very 
uncomfortable 
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2. Check whether you agree or disagree with the following statements: 
 Agree Disagree 
I think NIPT is pointless.   
NIPT is leading us down a slippery slope.   
I feel NIPT is just a way for labs to make money.   
NIPT is going to make prenatal diagnosis more complicated.   
I think NIPT will replace invasive procedures.   
As practitioners, we need more information/education about the 
test/technology. 
  
More studies are needed to establish clinical validity and utility.   
NIPT is going to revolutionize prenatal diagnosis.   
NIPT is going to simplify prenatal diagnosis.   
NIPT should currently be offered to patients not at increased risk.   
I think NIPT will replace maternal serum screening in the future.   
 
3. Which do you consider NIPT to be? 
a. A screen 
b. A diagnostic test 
c. Neither 
d. Unsure 
 
4. Introduction of this technology will: 
a. Reduce the number of invasive procedures performed. 
b. I am not sure how it will affect my practice. 
c. Not affect my practice. 
 
5. Do you think NIPT will eventually be the standard of care for evaluation of 
chromosome aneuploidy? 
a. Yes 
b. No 
c. Unsure 
 
Please provide us with any comments regarding this survey or NIPT: 
__________________________________________________________________________ 
__________________________________________________________________________ 
 
Thank you for your time!  This completes your participation in this study.  A donation will 
be made to the March of Dimes. 
 
If you would like to be contacted in the future to possibly participate in a follow up study, 
please enter your contact information below. If you do not wish to be contacted, please leave 
this field blank. 
Name: ________________________ 
Phone: ________________________ 
E-mail: ________________________ 
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Appendix B 
Research study (Survey) Regarding Obstetricians and Gynecologists attitudes toward and utilization of NIPT 
testing for chromosome aneuploidy 
 
You are invited to take part in a research project called, “Attitudes Toward and Utilization of Non-Invasive Prenatal 
Testing for Chromosome Aneuploidy Among OB/GYNs,” conducted by Jessica Davis, of the University of Texas Health 
Science Center. For this research project, she will be called the Principal Investigator or PI. 
 
The purpose of this research study is to determine the attitudes of obstetricians and gynecologists’ regarding non-invasive 
prenatal testing (NIPT) for chromosome aneuploidy and how they are incorporating the test into their clinical practice. 
 
NIPT is a newly commercialized technology that utilizes cell-free fetal DNA present in maternal serum in order to screen a 
pregnancy for a chromosome aneuploidy.  Chromosome aneuploidy refers to an abnormal number of chromosomes (1 or 3 
instead of the normal pair).  The most well known diagnosed chromosome aneuploidy is Trisomy 21 or Down syndrome.  
Other chromosome aneuploidies include Trisomies 13 and 18, and Klinefelter syndrome.  NIPT is currently validated in 
women who are at increased risk for an aneulpoidy.  Women at increased risk are traditionally defined as women with a 
1/270 chance or higher for Down syndrome, and 1/100 chance or higher for Trisomy 18 and 13. 
 
Non-invasive technology is used for other purposes, but for the sake of this survey, please refer to its detection of fetal 
chromosome aneuploidy. 
 
This study is composed of multiple-choice, yes or no, likert scale, and short answer questions, as well as statement 
agreements, which will allow us to better understand current practice regarding this topic. Space is available for additional 
comments should you find this necessary. There are no other alternative ways to participate in this study without filling out 
the survey below. There are no known risks for your participation in this study. 
 
Completion of this anonymous survey is voluntary and for research purposes only. It should take less than 15 minutes to 
complete this survey. All responses are completely confidential, and you will not be personally identified in any reports or 
publications of this study. Data will be summarized and presented as part of a thesis project at The University of Texas 
Graduate School of Biomedical Sciences at Houston and part of a session at the National Society of Genetic Counselor’s 
Annual Education Conference.  By completing and submitting the questionnaire, you are implying consent to have your 
answers used and shared among collaborators for this study.  You will not receive any financial compensation for 
completing the survey, however, for every survey completed a donation will be made to the March of Dimes. 
 
Although the results of this study will be useful for physicians and other health professionals, there may be no direct benefit 
to you for participating in this study. You can refuse to answer or skip any questions or stop taking the survey at any time. 
Refusing to take part or stopping at any point during the survey will involve no penalty. If you decide to participate in the 
study, it is very important that you answer the questions as honestly as you can. 
 
If you have any questions or concerns, please contact Jessica Davis or Kate Wilson, MS, CGC at (713) 486-2291. Thank 
you very much for your input regarding this important issue. 
 
Survey link: http://www.surveymonkey.com/s/NIPT_Survey 
 
Sincerely, 
Jessica Davis 
Genetic Counseling Student  
UT Health Science Center at Houston  
Graduate School of Biomedical Sciences  
Principal Investigator 
Kate Wilson, MS, CGC  
Genetic Counselor/Clinical Instructor  
UT Health Science Center at Houston  
Department of Obstetrics, Gynecology and Reproductive 
Sciences  
Committee Chair 
 
 
Survey link: http://www.surveymonkey.com/s/NIPT_Survey 
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